DAFTAR PUSTAKA

Abbas, Akhmadi., 2017. Monitoring Efek Samping Obat Anti-Tuberkulosis (OAT) Pada Pengobatan Tahap Intensif Penderita TB Paru Di Kota Makassar. ***Journal of Agromedicine and Medical Sciences*** Vol 3(1), p. 19-24.

Adeyemo, A. A., Oluwatosin, O., Omotade, Olayemi O., 2016. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. ***Springer Plus*** Vol 5(1):758, p. 1-9

Aditama, T. Y., 2013. Tuberkulosis, diagnosis, terapi dan masalahnya. Jakarta: ***Yayasan Penerbit IDI.***

Adriztina, Indri., Adnan, Adlin., Haryuna, Siti Hajar., Siagian, Parluhutan., Sarumpaet, Sorimuda., 2014. Gangguan Pendengaran dan Keseimbangan pada Penderita Tuberkulosis yang Mendapat Pengobatan Antituberkulosis Kategori 1 dan 2. ***Jurnal Kesehatan Masyarakat Nasional*** Vol 8(8), hal. 430-436.

Alghamdi, W. A., Al-Shaer, M. H., Peloquin, C. A., 2018. Protein bindung of first-line antituberculosis drugs. ***Antimicrobial Agents and Chemotherapy*** Vol 62(7), p. 1-7.

Amare H., Gelaw A., Anagaw B. and Gelaw B., 2013. Smear positive pulmonary tuberculosis among diabetic patients at the Dessie referral hospital, Northeast Ethiopia. ***Infectious Diseases of Poverty*** Vol 2(6), p. 90- 96.

Andayani, Sri., Astuti, Yoni., 2017. Prediksi Kejadian Penyakit Tuberkolosis Paru Berdasarkan Usia di Kabupaten Ponorogo Tahun 2016-2020. ***Indonesia Journal for Health Sciences*** Vol 1(2), hal. 29-33.

Arbex, M. A., Varella, M. C. L., de Siqueira, H. R., de Mello, F. A. F., 2010. Antituberculosis drugs: Drug interactions, adverse effect, and use in special situations. Part 1: First-line drugs. ***Journal Brasileiro de Pneumologia*** Vol. 36(5), p. 626-640.

Athira, B., Manju, CS., dan Jyothi E., 2015. A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. ***International Journal of Pharmacology and Clinical Sciences*** Vol 4(1), p. 7-11.

Atif, M., Sulaiman, S. A. S., Shafie, A. A., Muttalif A. R., Ali, I., Saleem, F., 2011. Pharmacokinetic concerns in the management of drug induced vomiting in co-morbid tuberculosis patient: A case report from Malaysia. ***Journal of Applied Pharmaceutical Sciences*** Vol 1(5), p. 69-71.

Badrinath, M., John, Savio., 2019. Isoniazid Toxicity. Treasure Island: ***SatpearlsPublishing.*** https://www.ncbi.nlm.nih.gov/books/NBK531488/.

Biswas, Anirban., Dutta, Nilotpal., 2018. Role of Betahistine in the Management of Vertigo. ***Annals of Otology and Neurotology ISO*** Vol 1(2), p. 51-57.

Brunton, LL. Et al., 2011. ***Goodman & Gilman's The Pharmacologycal Basis of Therapeutics. 12th edition.*** California: The McGraw-Hill Company.

Chung, H., Yoon, Y. H., Hwang, J. J., Cho, K. S., Koh, J. Y., Kim, J., 2009. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. ***Toxicology and Applied Pharmacology*** Vol 235, p. 162-170.

Cipolle, R.J. Strand, L.M. & Morley, P.C., 2012. ***Pharmaceutical Care Practice The Patient Centered Approach to Medication Management***. Third edition. New York: McGraw-Hill.

Delogu, Giovanni., Sali, Michela., Fadda, Giovanni., 2013. The Biology of *Mycobacterium Tuberculosis* Infection. ***Mediterranean Journal of Hematology and Infectious Diseases*** Vol 5(1).

Departemen Kesehatan Republik Indonesia (DEPKES RI), 2005. ***Pharmaceutical Care untuk Penyakit Tuberkulosis***. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik.

Dipiro, J. T., Schwinghammer, T. L., Wells, B. G., dan Dipiro, Cecily V., 2015. ***Pharmacotherapy Handbook 9th Edition.*** Section 8. Infectious Disease. Chapter 49. Tuberculosis. USA: The McGraw-Hill Companies., p. 476-489.

Dixit, Ramakant., George, Jacob., Sharma, Arun Kumar., 2012. Thrombocytopenia due to rifampicin. ***Lung India: Official Organ of Indian Chest Society*** Vol 29(1), p. 90-92.

Dotulong, Jendra F. J., Sapulete, Margareth R., Kandou, Grace D., 2015. Hubungan Faktor Risiko Umur, Jenis Kelamin dan Kepadatan Hunian dengan Kejadian Penyakit TB Paru di Desa Wori Kecamatan Wori. ***Jurnal Kedokteran Komunitas dan Tropik*** Vol 3(2), p. 57-65.

Fauziah, Nurul., Ahmad, Islamudin., Ibrahim, Arsyik., 2014. Karakteristik dan Analisis *Drug Related Problems* (DRPs) Pasien Penderita Tuberkulosis di Puskesmas Temindung Samarinda Kalimantan Timur. ***Journal of Tropical Pharmacy and Chemistry*** Vol 2(5), p 252-258.

Flomenbaum, N. E., Goldfrank, L. R., Hoffman, R. S., Howlan, M. A., Lewin, N. A., Nelson, L. S., 2006. ***Goldfrank's Toxicologic Emergencies,*** Ed 8th. New York: McGraw-Hill, p. 3405-3433.

Gerdan, Vedat., Akkoc, Nurullah., Ucan, Eyup Sabri., Bulac Kir, Serpil., 2010. Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia. ***Singapore Medical Journal*** Vol 54(6), p. 125-126.

Global Alliance for TB Drug Development, 2008. ***Handbook of Anti-Tuberculosis Agents Volume 88.*** New York: Elsevier Health.

Godreuil, Sylvain., Banuls, Anne-Laure., Sanou, Adama., dan Anh, Nguyen Thi Van., 2015. *Mycobacterium tuberculosis*: ecology and evolution of a human bacterium. ***Journal of Medical Microbiology*** Vol 64 p. 1261-1269.

Gulbay, Banu Eris., Gurkan, Ozlem Ural., Yildiz, Oznur Akkoca., Onen, Zeynep Pinar., Erkekol, Ferda Oner., Baccioglu, Ayse., dan Acican Turan., 2006. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. ***Respiratory Medicine*** Vol 100 p. 1834-1842.

Guo, H., Hassan, H. M., Ding, P., Wang, S., Chen, X., Wang, T., Sun, L., Zhang, L., Jiang, Z., 2017. Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2α-ATF4-CHOP pathway. ***Toxicology*** Vol 378, p. 65-75.

Hakim, Abdul N., Putri, Prima Maharani., 2015. Pengaruh Latar Belakang Pendidikan Pasien terhadap Keteraturan Pengobatan TB Paru di Puskesmas Wangon I Banyumas. ***Psycho Idea*** Vol 13(2), p. 1-13.

Herchline, Thomas E., Amorosa, Judith K., 2018. ***Tuberculosis (TB).*** Diakses dari www.emedicine.medscape.com, pada tanggal 12 November 2018.

Hutahaean, Lasmaria M., 2013. Effects of Smoking Habit on the Development of Tuberculosis Disease. ***Journal of Nursing and Health Science*** Vol 2(5), p. 24-29.

Hutari, Sari., Wongkar, MCP., Langi, Yuanita A., 2014. Hubungan Antara Tingkat Pendidikan, Pengetahuan dan Status Gizi dengan Pengobatan Tuberkulosis Paru Di Puskesmas Tuminting. ***Jurnal E-Clinic*** Vol 2(1).

Intiyati, Ani., Mukhis, Abdul., Arna, Yessy D., Fatimah, Siti., 2012. Hubungan Status Gizi dengan Kesembuhana Penderita TB Paru di Poli Paru di Rumah Sakit Daerah Sidoarjo. ***The Indonesian Journal of Health Science*** Vol 3(2), p. 60-74.

Irianti, T., Kuswandi., Yasin, N. M., Kusumaningtyas, R. A., 2016. ***Mengenal Anti-Tuberkulosis***. Yogyakarta: Grafika Indah.

Ittrich, Harald., Bockhom, Maximilian., Klose, Hans., Simon, Marcel., 2017. The Diagnosis and Treatment of Hemoptysis. ***Deutsches Ärzteblatt International*** Vol 114, p. 371-381.

Jeong, I., Park, J. S., Cho, Y. J., Yoon, H. I., Song, J., Lee, C. T., dan Lee, J. H., 2015. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. ***Journal of Korean medical science*** Vol 30(2), p. 167-172.

Juzmi, Nur Azizah., Umar, Batari Todja., Taufik, Rahasiah., 2014. Neuropai Optik Toksik Setelah Pemberian Etambutol pada Penderita Tuberkulosis di Makassar. ***Jurnal Sains dan Teknologi Kesehatan*** Vol 4(3). P. 269-276.

Kementerian Kesehatan Republik Indonesia (KEMENKES RI), 2014. ***Pedoman Nasional Pengendalian Tuberkulosis.*** Jakarta: Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia (KEMENKES RI), 2016. ***Survei Prevalensi Tuberkulosis 2013-2014***, Jakarta: Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia (KEMENKES RI), 2018. ***InfoDATIN Tuberkulosis***. Jakarta: Kementerian Kesehatan Republik Indonesia.

Kondo, Irwanto., Wongkar, M. C. P., Ongkowijaya, Jeffrey., 2016. Gambaran Kadar Asam Urat pada Penderita Tuberkulosis Paru yang Menerima Terapi Obat Anti Tuberkulosis di RSUP Prof. Dr. R. D. Kandou Manado Periode Juli 2014 – Juni 2015. ***Jurnal e-Clinic*** Vol 4(1), p. 344-348.

Koul, Parvaiz A., 2015. Ocular toxicity with ethambutol therapy: Timely recaution. ***Lung India: Official Organ of Indian Chest Society*** Vol 32(1), p. 1-3.

Kumar, V., Abbas, A. K., Aster, J. C., 2013. ***Robbins Basic Pathology 9th edition***. Philadelphia: Elsevier.

Kumar, Y. A., Ahmad, A., Kumar, V. R., Mohanta, G. P., Manna, K. P., 2012. Pharmacist Interventions and Pharmaceutical Care in and Indoan Teaching Hospital. ***International Journal of Advanced Research in Pharmaceutical and Bio Science*** Vol 2(3), p. 392-394.

Kurniangsih, Laela., Sudirman, Iskandar., Utaminingrum, Wahyu., 2010. Identifikasi *Drug Related Problems* (DRP) Pengobatan Tuberkulosis pada Pasien Rawat Jalan di RSUD Kardinah Kota Tegal tahun 2010. ***Pharmacy*** Vol 7(3), hal. 50-58.

Kurniawan, Nurmasadi., Rahmalia, Siti., Indriati, Ganis., 2015. Faktor-Faktor yang Mempengaruhi Keberhasilan Pengobatan

Tuberkulosis Paru. ***Jurnal Online Mahasiswa Bidang Kedokteran*** Vol 2(1), hal. 729-741.

Kurniawati, Fivy., Sulaiman, Syed Azhar Syed., Gillani, Syed Wasif., 2012. Adverse Drug Reactions of Primary Anti-tuberculosis Drugs Among Tuberculosis Patients Treated in Chest Clinic. ***International Journal of Pharmacy and Life Sciences*** Vol 3(1), p. 1331-1338.

Leshinsky, Stacey Singer., 2016. Pulmonary tuberculosis: Improving diagnosis and management. ***Journal of the American Academy of Physician Assistant*** Vol 29(2), p. 20-25.

Lima, Maria L. L. T., Lessa, Fabio., Aguiar-Santos, Ana Maria., Medeiros, Zulma., 2006. Hearing Impairment in Patients with Tuberculosis from Northeast Brazil. ***Revista do Instituto de Medicina Tropical de Sao Paolo*** Vol 48(2), p. 99-102.

Luthariana, Lies., Karjadi, Teguh H., Hasan, Irsan., Rumende, C. Martin., 2017. Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Antituberkulosis pada Pasien HIV/AIDS. ***Jurnal Penyakit dalam Indonesia*** Vol 4(1), hal. 23-28.

Maria, Nisa., Radji, Maksum., Burhan, Erlina., 2017. The Impact of Antituberculosis Drug-Induced Hepatotoxicity to Succesful Tuberculosis Treatment in Indonesia. ***Asian Journal of Pharmaceutical and Clinical Research*** Vol 10(11), p. 194-198.

Maulidya, Yulinda Nur., Redjeki, Endang Sri., Fanani, Erianto., 2017. Faktor yang Mempengaruhi Keberhasilan Pengobatan TB Paru pada Pasien Pasca Pengobatan di Puskesmas Dinoyo Kota Malang. ***Preventia: The Indonesian Journal of Public Health*** Vol 2(1).

Moon, Myung-Sang., Moon, Hanlim., dan Kim, Sung-Soo., 2015. Tubercle Bacilli in Spinal Tuberculosis - Morphology, Cell Wall Features, Behaviour and Drugs. ***Journal of Spine*** Vol 4(6).

Mustikawangi, Vivin., Rambert, Glady I., Wowor, Mayer., 2016. Gambaran pemeriksaan makroskopis urin pada pasien tuberculosis dewasa di RSUP Prof. Dr. R. D. Kandou Manado. ***Jurnal e-Biomedik (eBm)*** Vol 4(2).

Niazi A.K, Kalra S., 2012. Diabetes and tuberculosis: a review of the role of optimal glycemic control**.** ***Journal of Diabetes & Metabolic Disorders*** Vol 11(28).

Ningrum, Vitarani D. A., Megasari, Arnia., Hanifah, Suci., 2010. Hepatotoksisitas pada Pengobatan Tuberkulosis di RSUD Tangerang-Indonesia. ***Jurnal Ilmiah Farmasi*** Vol 7(1), p. 39-47.

Okamura, Kyoko., Nagata, Nobuhiko., Wakamatsu, Kentaro., Yonemoto, Koji., Ikegame, Satoshi., Kajiki, Akira., Takayama, Koichi., Nakanishi, Yoichi., 2013. Hypoalbuminemia and Lymphocytopenia are Predictive Risk Factors for In-hospital Mortality in Patients with Tuberculosis. ***Internal Medicine*** Vol 52, p. 439-444.

Pandit, Aashish., Sachdeva, Tarun., Bafna, Pallavi., 2012. Drug-Induced Hepatotoxicity: A review. ***Journal of Applied Pharmaceutical Science*** Vol 2(5), p. 233-243.

Pham, Anthony Q., Doan, Anh., Andersen, Matt., 2014. Pyrazinamid-Induced Hyperuricemia. ***Pharmacy and Therapeutics*** Vol 39(10), p. 695-697.

Pharmaceutical Care Network Europe (PCNE). 2017. ***PCNE Classification for Drug Related Problems V8.02***, Pharmaceutical Care Network Europe.

Perhimpunan Dokter Paru Indonesia (PDPI). 2006. ***Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia.*** Diakses dari www.klikpdpi.com, pada tanggal 19 November 2018.

Pratomo, IP., Burhan, E., Tambunan, V., 2012. Malnutrisi dan Tuberkulosis. ***Journal of the Indonesian Medical Association*** Vol 62(6), hal. 230-237.

Prihanti, G. S., Sulistiyawati., Rahmawati, Ina., 2015. Analisis Faktor Risiko Kejadian Tuberkulosis Paru. ***Medika*** Vol 11(2), p. 127-132.

Putri, Wina Astari., Munir, Sri Melati., Christianto, Erwin., 2016. Gambaran Status Gizi pada Pasien Tuberkulosis Paru yang Menjalani Rawat Inap di RSUD Arifin Achmad Pekanbaru. ***Jurnal Online Mahasiswa FK*** Vol 3(2), p. 1-16.

Puspasari., Yamanie, Nizar., Octaviana, Fitri., Prihartono, Joedo. 2011. Neuropati Perifer pada Pemberian Obat Anti Tuberkulosis Lini Pertama berdasarkan Pemeriksaan Nerve Conduction Study dan Faktor-Faktor yang Memengaruhinya. ***Neurona*** Vol 29(1).

Ramappa, Vidyasagar., Aithal, Guruprasad P., 2013. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management., ***Journal of Clinical adn Experimental Hepatology*** Vol 3(1), p. 37-49.

Reither, R. J., Tan, D. X., Korkmaz, A., Fuentes-broto, L., 2011. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin. ***Journal of Physiology and Pharmacology*** Vol 62(2), p. 151-157.

Restrepo, Blanca I., 2016. Diabetes and Tuberculosis. ***Microbiology Spectrum*** Vol 4(6), doi: 10.1128/microbiolspec.TNM17-0023-2016.

Ruditya, Dea Nurma., 2015. Hubungan Antara Karakteristik Penderita TB dengan Kepatuhan Memeriksakan Dahak selama Pengobatan. ***Jurnal Berkala Epidemiologi*** Vol 3(2), p. 122-133.

Safithri, Fathiyah., 2011. Diagnosis TB Dewasa dan Anak Berdasarkan ISTC *(International Standard for TB Care).* ***Saintika Medika*** Vol 7(15), hal 57-67.

Schatz, Stephanie., Weber, Robert J., 2015. Adverse Drug Reactions. ***Pharmacotherapy Self Assessment Program***, p. 5-26.

Sengul, Aysun., Akturk, Ulku Aka., Aydemir, Yusuf., Kaya, Nurullah., Kocak, Nagihan Durmus., Tasolar, Fatma Turan., 2015. Factors affecting successful treatment outcomes in pulmonary tuberculosis: a single-center experience in Turkey, 2005–2011. ***The Journal of Infection In Developing Countries*** Vol 9(8), p. 821-828.

Serafino, Robert L., 2013. Tuberculosis 2: Pathophysiology and Microbiology of Pulmonary Tuberculosis. ***South Sudan Medical Journal*** Vol 6(1), p. 10-12.

Shah, Maunank., Reed, Caitlin., 2014. Complications of Tuberculosis. ***Current Opinion in Infectious Diseases*** Vol 27(5), p. 403-410.

Shanmuganathan, Rohan., Shanmuganathan, Indra Devi., 2014. Clinical Manifestation and Risk Factors of Tuberculosis Infection in Malaysia: Case Study of a Community Clinic. ***Global Journal of Health Science*** Vol 7(4), p. 110-120.

Siddiqui, Ali Nasir., Khayyam, Khalid Umer., Sharma, Manju., 2016. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study. ***Biomed Research International*** Vol 2016:7273935. doi: 10.1155/2016/7273935.

Silva, Denise Rossato., Munaz-Torrico, Marcela., Duarte, Raquel., Galvao, Tatiana., Bonini, Eduardo Henrique., Arbex, Flavio., Arbex, Marcos., Augusto, Valeria., Rabahi, Marcelo Fouad., Mello, Fernanda C., 2018. ***Journal Brasileiro de Pneumologia*** Vol 44(2), p. 145-152.

Singh, Abhijeet., Prasad, Rajendra., Balasubramanian, Viswesvaran., Gupta, Nikhil., Gupta, Pawan., 2015. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. ***Clinical Epidemiology and Global Health*** Vol 3(1) p. 80-90.

Stettner, M., Steinberger, D., Hartmann, C. J., Pabst, T., Konta, L., Hartung, H. P., Kieseier, B. C., 2015. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?. ***Brain and behavior*** Vol 5(8), e00326.

Sukandar, Elin Yulinah., Hartini, Sri., Hasna., 2012. Evaluasi Penggunaan Obat Tuberkulosis pada Pasien Rawat Inap di Ruang Perawatan kelas III di Salah Satu Rumah Sakit di Bandung. ***Acta Pharmaceutica Indonesia*** Vol 37(4), p. 153-158.

Susilayanti, E. Y., Medison, Irvan., Erkadius. Profil Penderita Penyakit Tuberkulosis Paru BTA Positif yang Ditemukan di BP4 Lubuk Alung periode Januari 2012-Desember 2012. ***Jurnal Kesehatan Andalas*** Vol 3(2), p. 151-155.

Swart, Annoesjka., Harris, Vaness., 2005. Drug Interactions with Tuberculosis Therapy. ***Continuing Medical Education Journal*** Vol 23(2) p. 56-60.

Sweetman, Sean C., 2009. ***Martindale: The Complete Drug Reference 36th edition***. London: Pharmaceutical Press.

Tatro D., 2001. ***Drug Interaction Fact.*** California: Abd Comparisons Publishing Group.

Tatro, D. S., 2009. ***Drug Interaction Facts***. California: Wolters Kluwer Health, Inc.

Torrent, Josep., Izquierdo, Inaki., Cabezas, Ricardo., Jane, Francesc., 1989. Theophylline-Isoniazid Interaction. ***The Annals of Pharmacotherapy*** Vol 23, p. 143-145.

Umam, Khairil., Ramdhani, Yulia., Zulfikar., 2017. Efek Kadar Albumin Terhadap Perbaikan Klinis Pasien TB di Instalasi Pelayanan Tuberkulosis Terpadu (PTT) RSUDZA. ***Jurnal Ilmiah Mahasiswa Kedokteran Biomedis*** Vol 2(4), hal 8-14.

Unissa, Ameerudin Nusrath., Hanna, Luke Elizabeth., 2017. Molecular mechanism of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and Pyrazinamide. ***Tuberculosis*** doi: 10.1016/j.tube.2017.04.008.

Vasava, Mahesh S., Bhoi, Manoj N., Rathwa, Sanjay K., Borad, Mayuri A., Nair, Sneha G., Patel, Hitesh D., 2017. Drug development against tuberculosis: Past, present and future. ***Indian Journal of Tuberculosis*** Vol 186, p. 1-24.

Wahyudi, Andri Dwi., Soedarsono., 2015. Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis. ***Jurnal Respiras*** Vol 1(3), hal.103-108.

Wallace, J. L., Sharkey, K. A., 2011. Chapter 45: Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. In: Brunton, L., Chabner, B., Knollman, B., ***Goodman & Gilman's The Pharmacological Basis of Therapeutics***. 12th Ed. New York: McGraw-Hill Medical, p. 1310.

Wang, P., Pradhan, K., Zhong, X. B., Ma, X., 2016. Isoniazid metabolism and hepatotoxicity. ***Acta pharmaceutica Sinica*** Vol 6(5), p. 384-392.

Wijaya, Indra., 2015. Tuberkulosis Paru pada Penderita Diabetes Melitus. ***Continuing Medical Education Journal*** Vol 42(6), p. 412-417.

Winston, Lisa G., Beauduy, Camille E., 2017. Antimycobacterial Drugs. In: ***Basic & Clinical Pharmacology 14th Edition***. Katzung, Bertram G. (editor). USA: The McGraw-Hill Education p. 842-852.

World Health Organization (WHO), 2018. ***Global Tuberculosis Report***. Diakses dari www.who.int, pada tanggal 22 Oktober 2018.

Yee, Daphne., Valiquette, Chantal., Pelletier, Marthe., Parisien, Isabelle., Rocher, Isabelle., dan Menzies, Dick., 2003. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. ***American Journal of Respiratory and Critical Care Medicine*** Vol 167 p. 1472-1477.

Zhang. X., Andersen, A. B., Lillebaek, T., Kamper-Jorgensen, Z., Thomsen, V. O., Ladefoged, K., Marrs, C. F., Zhang, L., Yang, Z., 2011. Effect of Sex, Age. And Race on the Cinical Presentation of Tuberculosis: a 15-year population based study. ***The American Journal of Tropical Medicine Hygine*** Vol 85(2), p. 285-290.

Zhang, Y., Shi, W., Zhang, W., Mitchison, D., 2013. Mechanisms of Pyrazinamid Action and Resistance. ***Microbiologu spectrum*** Vol 2(4), p. 1-12.

Zumla, Alimuddin., Raviglione, Mario., Hafner, Richard., Reyn, C. Fordham von., 2013. Current Concepts Tuberculosis. ***The New England Journal of Medicine*** Vol 368(8), p. 745-755.